Texas Capital Bancshares stock hits 52-week low at $18.68

Freedom Capital has raised its price target for Nutex Health stock (NASDAQ:NUTX) to $306.00, up from $280.00, while retaining a Buy rating. The company's stock is currently trading at $213.31, having delivered a 111% return over the past year. InvestingPro analysis suggests the stock is still undervalued, trading near its 52-week high of $224.28.

During two days of investor meetings in the Midwest, Nutex management expressed confidence in the company's growth prospects, indicating no material near-term headwinds. They view the second-quarter 2026 revenue as the baseline for future performance. Management believes the reimbursement debate has shifted in favor of providers following the Fifth Circuit's en banc TMA III decision.

Investors raised questions about payer pushback, the sustainability of IDR economics, and how to model revenue per visit and new-unit contribution. Nutex plans to open more than 10 hospitals through 2028, targeting roughly 38 hospitals by the end of that year. The company's EBITDA of $502 million over the past 12 months backs management's estimate of $10 million per mature unit.

For a more in-depth look at Nutex's expansion strategy and financial health, investors can access the comprehensive Pro Research Report, available on InvestingPro for this and nearly 1,400+ other US stocks. The firm's new price target is based on six times its 2028 exit-rate EBITDA estimate, discounted two years and factoring in Nutex's net cash position.